Health Care · Services-Health Services

INNV InnovAge Holding Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 183437663 filings
Russell 2000

INNV at a glance

InnovAge Holding Corp. (INNV, SEC CIK 1834376) filed its latest 10-K annual report on September 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), InnovAge Holding Corp. (INNV) reported revenue of $989.7 million (up 15.9% from FY2025) and a net loss of $2.5 million. Diluted EPS was -$0.02.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding InnovAge Holding Corp. (INNV) shares worth $75.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by DAMATO NICOLE on October 22, 2026 of 3,402 shares at $9.51 per share.
  • In the last 90 days, INNV insiders reported 0 open-market purchases ($0) and 8 open-market sales ($226.9M) on Form 4, a net sale of $226.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$989.7M
+15.9% vs prior year
Insiders · 90 days
0 buys · 8 sells
Net −$226.9M
13F holders
23 funds
$75.7M · −1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Business Overview

  • Core business: All-inclusive, capitated healthcare delivery via PACE targeting high-cost, dual-eligible seniors to enable aging at home
  • New emphasis on de novo centers launched in Florida (Tampa, Orlando) and joint ventures with Orlando Health and Tampa General Hospital in 2026
  • Strategic shift: Increased focus on technology and data analytics investments to enhance care coordination and payor capabilities
  • Quantitative: Served ~8,230 participants (largest US PACE provider), operating 20 centers across 6 states, with 2,500 employees (1,600+ clinical)
  • Noteworthy: 2026 I-SAT participant satisfaction NPS of 52 vs national PACE average 59, demonstrating strong engagement despite growing complexity of participants

Risk Factors

  • Regulatory risk: False Claims Act allegations with DOJ and Colorado AG; $37M accrual recorded Q4 FY26, investigation ongoing, may cause material losses or penalties
  • Macroeconomic threat: Labor shortages and California SB 525 wage increases raised FY26 care costs; 70.2% revenue from CA and CO exposes to state budget cuts
  • Operational risk: California PACE application pause (Nov 2025-Nov 2027) limits new center openings and expansions, restraining CA market growth
  • Competitive risk: Medicare Advantage Special Needs Plans and ACOs pose competition for participants; expansion into new states faces competitors with stronger local presence
  • Financial risk: $48.8M outstanding Term Loan A debt with restrictive covenants may constrain operational flexibility and increase refinancing risk

Management Discussion & Analysis

  • Revenue $989.7M, up 15.9% YoY driven by $988.4M capitation revenue (16.0% increase, +$136.0M) from member growth and rate hikes
  • Operating income $2.6M vs loss $(29.8)M; net loss $(0.7)M vs $(35.3)M; adjusted EBITDA margin 9.6% vs 4.0% driven by revenue growth and margin improvement
  • Best segment PACE with Center-level Contribution Margin $227.8M, 23.0% of revenue vs $153.6M, 18.0% prior year; Senior Housing segment minimal, below reporting threshold
  • Operating cash flow $64.7M, capex $12.3M, financing cash outflow $18.5M including share repurchases; debt $48.8M with $93.8M available under revolving credit
  • FY27 risk from Medicaid rate reductions (e.g., Colorado) and California PACE moratorium; increasing care costs expected but partially offset by initiatives; management investing in growth and clinical value

AI summary of the INNV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $264.8M, up 12.1% YoY from $236.1M, driven by higher capitation rates and member months
  • Net income margin 7.9% vs 3.2% YoY; Adjusted EBITDA margin 11.8% vs 7.5%
  • Center-level Contribution Margin $63.6M, 24.0% of revenue vs $51.4M and 21.8% YoY
  • Cash and equivalents $119.3M, up $21.4M; operating cash flow $28.7M vs $3.9M YoY
  • Expected Medicaid rate pressures and higher provider costs in fiscal 2027, with Colorado rates decreasing retroactively

AI summary of the INNV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q1 fiscal 2026 results for the quarter ended September 30, 2026 announced by press release
  • Exhibit 99.1 contains the financial results and related investor-relevant commentary

Item EX-99.1: Item EX-99.1

  • Fiscal Q1 2027 revenue $264.8M, up 12.1% year over year, supported by census growth to approximately 8,420 participants
  • Net income $20.9M, up from $7.7M, with margin expanding to 7.9% from 3.2%
Filed Sep 24, 2026Full analysis →

Item 8.01: Other Events

  • Selling shareholder sold 10,000,000 InnovAge shares at $9.25 each through an underwritten offering
  • Company receives no proceeds, limiting balance-sheet benefit and signaling shareholder-level liquidity rather than corporate fundraising
Filed Sep 8, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal fourth-quarter and full-year results ended June 30, 2026 announced
  • Press release issued September 8, 2026, with detailed financial results in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FY2026 revenue $989.7M, up 15.9%, supported by census growth to approximately 8,230 participants
  • Adjusted EBITDA $94.6M, up from $34.5M, with margin expanding to 9.6% from 4.0%

AI summaries of INNV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INNV

Don't miss the next INNV filing

  • Alerts as it files. A push when INNV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INNV, by share count.
  • Ask anything. An AI agent that reads every INNV filing and answers with sources.

INNV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DAMATO NICOLESellOct 22, 2026$9.51
Welsh, Carson, Anderson & Stowe XII, L.P.SellOct 21, 2026$9.25
TCO GROUP HOLDINGS, L.P.SellOct 21, 2026$9.25
IGNITE AGGREGATOR LPSellOct 21, 2026$9.25
DAMATO NICOLESellSep 25, 2026$8.70
Welsh, Carson, Anderson & Stowe XII, L.P.SellSep 24, 2026-
TCO GROUP HOLDINGS, L.P.SellSep 24, 2026$9.25
IGNITE AGGREGATOR LPSellSep 24, 2026$9.25

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue$763.9M$853.7M$989.7M
Gross Profit-$153.6M$227.8M
Operating Income--$29.8M$2.6M
Net Income--$30.3M-$2.5M
Gross Margin-18.0%23.0%
Op. Margin--3.5%0.3%
Net Margin--3.6%-0.3%
Balance Sheet
Total Assets-$526.9M$557.4M
Equity-$235.0M$235.6M
ROE--12.9%-1.1%
Per Share
EPS-$-0.22$-0.02
Cash Flow
Operating CF-$32.9M$64.7M
CapEx$7.9M$6.3M$14.3M

Source: XBRL data in InnovAge Holding Corp. (INNV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate INNV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INNV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$75.7M
Q2 202624$58.6M
Q1 202624$33.6M
Q4 202520$19.1M
Q3 202517$18.1M
Q2 202519$12.8M
Q1 202514$6.7M
Q4 20249$9.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INNV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 26, 2026--
4Oct 23, 2026--
4Oct 23, 2026--
4Oct 23, 2026--
4Sep 29, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
8-KSep 24, 2026Analysis-
10-KSep 9, 2026Analysis
8-KSep 8, 2026Analysis-
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Jul 27, 2026--
4Jul 23, 2026--
4Jul 23, 2026--
4Jul 23, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--

Related Health Care companies

All Health Care →

INNV SEC filings: frequently asked questions

Are INNV insiders buying or selling?

In the last 90 days, InnovAge Holding Corp. (INNV) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $226.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold INNV stock?

As of September 30, 2026, the largest InnovAge Holding Corp. (INNV) holders among the 13F filers tracked by SignalX were Citadel Advisors LLC ($14.3 million), BlackRock ($12.8 million), Vanguard Capital Management LLC ($12.0 million), Millennium Management ($7.2 million), Goldman Sachs Group ($5.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INNV's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), InnovAge Holding Corp. (INNV) reported revenue of $989.7 million (up 15.9% from FY2025) and a net loss of $2.5 million. Diluted EPS was -$0.02. The figures come from the XBRL data in the 10-K.

What are the main risks in INNV's latest 10-K?

In the 10-K filed September 9, 2026, InnovAge Holding Corp. (INNV) flagged: Regulatory risk: False Claims Act allegations with DOJ and Colorado AG; $37M accrual recorded Q4 FY26, investigation ongoing, may cause material losses or penalties. Macroeconomic threat: Labor shortages and California SB 525 wage increases raised FY26 care costs; 70.2% revenue from CA and CO exposes to state budget cuts. (AI summary of the Risk Factors section.)

What did INNV report in its latest 8-K?

InnovAge Holding Corp. (INNV) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 fiscal 2026 results for the quarter ended September 30, 2026 announced by press release.

What are the latest INNV SEC filings?

InnovAge Holding Corp. (INNV) filed its latest 10-K annual report on September 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 26, 2026.

What is INNV's SEC CIK number?

InnovAge Holding Corp. (INNV)'s SEC Central Index Key (CIK) is 1834376. EDGAR lists every INNV filing under that number.

Ask anything about INNV

The research agent reads INNV's filings, financials, insider trades and 13F holders, then answers with sources.